AlphaSense says it “is not a life sciences database,” so pharma teams buy one alongside it. Sleuth searches the same biopharma documents and builds one table across every program from its own knowledge base.
Sleuth has the documents you use AlphaSense for, analyst research included, and a knowledge base of drugs, trials, companies, and deals. It builds the table for your question from both.
Landscapes, partner and asset searches, and analyst research across every program, without a separate database or a week in Excel.
Your team relies on its expert and KOL call transcripts, or researches industries outside life sciences.
An AlphaSense seat
Priced by its sales team
An annual contract, per seat. Which analyst reports you can open depends on your company’s account with each bank.
Sleuth
From $249 a month
Analyst research from 35+ providers comes with every plan, with no account needed at each bank.
Sleuth
AlphaSense
Sleuth
Analysis built for your question, from a biopharma knowledge base and the documents behind it.
AlphaSense
A research platform for business and finance. In its own words, it “is not a life sciences database.”
Sleuth
150K+ drugs, 1M+ trials from 20 registries, 400K+ companies, and 200K+ deals, connected in one knowledge base.
AlphaSense
Not included. Pharma teams buy a database such as Cortellis or Evaluate alongside it.
Sleuth
One row per program, built from every record and document about it, in the columns you need.
AlphaSense
Its table tool summarizes one document per row, so a program covered in 30 documents takes 30 rows.
Sleuth
Sell-side research from 35+ providers in every plan. Read any report in full, with no account needed at each bank.
AlphaSense
Broker research from many more banks. Which reports you can open depends on your company’s account with each bank.
Sleuth
Biopharma only: 5M+ corporate documents, 5M+ news articles and press releases, 300K+ patents, and conference abstracts.
AlphaSense
“A purpose-built financial research platform.” Most of its library covers other industries.
Sleuth
Click any value to see the filing, registry entry, or broker note behind it, with its date, a confidence score, and whether it’s sourced, inferred, or unknown. Sleuth flags the few cells worth checking.
AlphaSense
You check each answer yourself. It cites the passage it read, with no score for how much to trust the value.
Sleuth
Not included for now. Sleuth works from public documents, licensed data, and sell-side research.
AlphaSense
Expert and KOL call transcripts, and calls you set up yourself.
Sleuth
From $249 a month, with published prices. Start today with a 14-day trial, no card.
AlphaSense
Annual contracts, per seat or for the enterprise, priced by its sales team.
Sleuth puts a program’s phase and deals from the knowledge base next to what its filings, abstracts, and analyst notes say. Click any value to open the record or page it came from.
AlphaSense’s Generative Grid puts one document in each row and summarizes it. Sleuth builds one row per program from every record and document about it, in the columns you need.
“Which TROP2 ADCs are in Phase 3 or approved, and what were their latest deal and readout?”
Every program that fits, including private Chinese companies’ programs that no analyst covers.
Click a cell to see the abstract, filing, or deal record behind it.
Saved to your Studio account, and exported to Excel, a deck, or an interactive analysis.
Based on second-quarter earnings, the median top-15 pharma company has about $24 billion of acquisition capacity.
Sleuth analyzed 4,773 unique abstracts before the May 2026 meeting.
About 1,025 China-originated drugs are approved somewhere in the world, and 34 of them in the US.
Keep AlphaSense if your team relies on its expert and KOL call transcripts, or researches industries outside life sciences. For biopharma landscapes, partner searches, and analyst research, Sleuth covers the work.
Transcripts of expert and KOL interviews, and calls you set up yourself. Sleuth doesn’t offer these for now.
Research on companies and markets in technology, energy, consumer goods, and other sectors.
Standardized financials and models for companies outside biopharma.
For biopharma work, yes: landscapes, partner and asset searches, and analyst research. Keep AlphaSense if your team relies on its expert and KOL call transcripts, or researches industries outside life sciences.
It does, and each row is one document you pick, summarized. AlphaSense’s help center says its results “are generated based on documents only — not companies directly.” In Sleuth, each row is a program, built from every record and document about it.
Sleuth’s prices are published: Starter is $249 a month, and Team plans start at $499 a month for any number of people. Sell-side research comes with every plan, and you don’t need an account with each bank. AlphaSense sells annual contracts, per seat or for the enterprise, through its sales team.
Sell-side research from 35+ providers: global and US healthcare banks, European brokers, independent research, and consulting firms, plus archives back to 2017 and China’s domestic brokers in English. Ask us for the full list.
Not for now. If expert and KOL calls are a big part of your research, keep AlphaSense or an expert network for them.
Yes. Sleuth works in Claude, ChatGPT, and Copilot on every plan. A project you run from an AI tool draws on the same analyst research, and the reports open in that project in Studio.